Navigation Links
NuPathe Reports Positive Phase One Results for NP101 Transdermal,Therapy for Acute Migraine

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Jun 8, 2007 - NuPathe Inc., a privately held specialty pharmaceutical company, today announced positive results from an initial Phase I study of NP101 SmartRelief, a novel treatment for acute migraine being developed by NuPathe.

NP101 combines NuPathe's SmartRelief(TM) proprietary iontophoretic transdermal technology with sumatriptan, the most widely prescribed treatment for acute migraine in the United States. Sumatriptan is also the active ingredient in IMITREX(R), which is also indicated for the treatment of acute migraine.

The study was a randomized, single-center, single-dose, six-period pilot study to evaluate four SmartRelief(TM) prototypes. The study compared sumatriptan pharmacokinetics and safety following administration of NP101 SmartRelief(TM) prototype patches, IMITREX 50 mg tablets, and IMITREX 6 mg subcutaneous injection. Results of the Phase I study were presented today in a poster presentation at the American Headache Society meeting in Chicago.

In the study, NP101 maintained continual therapeutic dosing levels of sumatriptan an average of four times longer than treatment with the 6 mg injection of IMITREX and up to twice as long as treatment with the 50 mg tablet of IMITREX. NP101 was also generally well tolerated.

"These results demonstrate that NuPathe's transdermal technology can deliver therapeutic drug levels quickly and then maintain those levels over a sustained period of time, which may significantly improve consistency of response and decrease frequency of recurrent migraines in patients," said Steven J. Siegel, MD, PhD, assistant professor, University of Pennsylvania, who presented the results in Chicago. "This controlled delivery option could represent an important alternative for patients who experience gastrointestinal disorders such as nausea and vomiting during their migraine attack."

According to Jane Hollingsworth , CEO of NuPathe, "Patients need better options for treatment of acute migraine attacks. Triptans, which are considered the gold standard in treatment today, are proven to be efficacious, but they often result in inconsistent response, nausea, and recurrent headaches. Through NuPathe's patented transdermal delivery system, NP101 is designed to deliver sumatriptan in a consistent and sustained manner through a patch, significantly reducing the risk of GI problems."

About Migraine

Migraine is a widespread, chronic condition that affects approximately 25 million Americans. The primary symptoms include intense and disabling headache, acute sensitivity to light and sound, nausea, and aura. Some experts estimate that the loss of productivity associated with migraine costs the US economy between $13 and $17 billion each year. (1)

About Iontophoresis

Iontophoresis is a non-invasive process for actively transporting drugs through the skin and into underlying tissue. During iontophoresis charged molecules are propelled through the skin using bi-polar electrical fields. Iontophoretic products have been approved for multiple medical and therapeutic uses.

About NuPathe

NuPathe specializes in the development of therapeutics for the treatment of neurological and psychiatric disorders including migraine, Parkinson's disease and schizophrenia. NuPathe's lead product, NP101, uses SmartRelief(TM), the company's novel, transdermal patch technology, to deliver sumatriptan, a widely-used therapy for the treatment of acute migraine. Pending regulatory review and approval, NP101 would be the first ever migraine treatment based on a transdermal patch delivery. Phase I clinical results for NP101 have thus far demonstrated rapid delivery of migraine medication and improved pharmacokinetics compared to current standard of care. For additional information, visit www.nupathe.com.

(1) Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of m igraine in the United States: disability and economic costs. Arch Intern Med 1999; 159(8):813-818.

Contact

NuPathe Inc.
by
Berry & Company

Kim Angelastro, 212-253-8881
kangelastro@berrypr.com


'"/>




Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Surgical Procedure Volumes: Global Analysis (United States, ... Australia, Canada)" report to their offering. ... an essential tool for healthcare business planners, provides surgical ... looks at surgery trends with an in-depth analysis of ...
(Date:6/23/2016)... , June 23, 2016 ... but it continues to present great opportunities to investors. ... for today: Intrexon Corp. (NYSE: XON ), ... Pharmaceuticals Inc. (NASDAQ: ARNA ), and Regeneron ... about these stocks and receive your complimentary trade alerts ...
(Date:6/23/2016)... 23, 2016 Leading BioSciences Inc., a ... conditions resulting from a breakdown of the mucosal ... Greg Doyle as chief executive officer. Mr. ... management team and board of directors, previously served ... He will provide continued leadership and strategic direction ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
Breaking Medicine News(10 mins):